Symbols

AUPH

Aurinia·NASDAQ

--(--)

AUPH fundamentals

AUPH Q4 2025 Earnings

Aurinia (AUPH) released its earnings on Feb 26, 2026: revenue was 77.11M (YoY +28.81%), beat estimates; EPS was 1.53 (YoY +15200.00%), beat estimates.

Revenue / YoY

77.11M

+28.81%

EPS / YoY

1.53

+15200.00%

Report date

Feb 26, 2026

AUPH Earnings Call Summary for Q4,2025

Revenue Growth: 25% YoY LUPKYNIS sales in 2025, with 2026 guidance of $305-$315 million (+12-16%).
Financial Strength: FY 2025 net income $287.2 million, cash flow $135.7 million, and $398 million cash balance.
Pipeline Momentum: Aritinercept advancing into two autoimmune disease studies; LUPKYNIS maintains competitive edge with rapid proteinuria reduction.
Market Dynamics: U.S. market dominates, while international growth constrained by pricing. Gazyva's launch unlikely to impact near-term LUPKYNIS performance.

Earnings

EPS

Revenue

Revenue & Expenses

AUPH has released its 2025 Q4 earnings report, with revenue of 77.11M, reflecting a YoY change of 28.81%, and net profit of 210.79M, showing a YoY change of 14651.15%. The Sankey diagram below clearly presents AUPH's revenue sources and cost distribution.

Key Indicators

Aurinia (AUPH) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Aurinia (AUPH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Aurinia (AUPH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Aurinia (AUPH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown